18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Public ClinicalTrials.gov record NCT01806675. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Study identification
- NCT ID
- NCT01806675
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Sanjiv Sam Gambhir
- Other
- Enrollment
- 25 participants
Conditions and interventions
Conditions
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Male Breast Cancer
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Adult Brain Tumor
- Recurrent Basal Cell Carcinoma of the Lip
- Recurrent Colon Cancer
- Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Hypopharyngeal Cancer
- Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Laryngeal Cancer
- Recurrent Lip and Oral Cavity Cancer
- Recurrent Lymphoepithelioma of the Nasopharynx
- Recurrent Lymphoepithelioma of the Oropharynx
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary
- Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Recurrent Nasopharyngeal Cancer
- Recurrent Non-small Cell Lung Cancer
- Recurrent Oropharyngeal Cancer
- Recurrent Pancreatic Cancer
- Recurrent Paranasal Sinus and Nasal Cavity Cancer
- Recurrent Rectal Cancer
- Recurrent Renal Cell Cancer
- Recurrent Salivary Gland Cancer
- Stage IIIA Breast Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Breast Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVA Salivary Gland Cancer
- Stage IVB Colon Cancer
- Stage IVB Salivary Gland Cancer
- Stage IVC Salivary Gland Cancer
- Tongue Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- 18F-FPPRGD2 Drug
- 18F-fludeoxyglucose (18F-FDG) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2013
- Primary completion
- Dec 6, 2016
- Completion
- Mar 31, 2019
- Last update posted
- Oct 2, 2019
2013 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University, School of Medicine | Stanford | California | 94305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01806675, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2019 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01806675 live on ClinicalTrials.gov.